Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

X
Trial Profile

Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MEDITREME
  • Most Recent Events

    • 10 Apr 2024 Primary endpoint (3 months and 6 months progression-free survival (PFS) rate) of 3-month PFS in MSS patients has been met.
    • 10 Apr 2024 Results assessing combination of durvalumab-tremelimumab with mFOLFOX6 in RAS-mutated metastatic colorectal cancer, presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 23 Sep 2023 Results assessing the immune response observed following immune monitoring of patients before and during MEDITREME trial, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top